Navigation Links
Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders
Date:11/7/2008

KANSAS CITY, Mo., Nov. 7 /PRNewswire/ -- In refusing to a request for a special shareholders meeting to consider the removal and replacement of its current directors, management of Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts ("ADRs) are traded on NASDAQ, has apparently decided that the preservation of their jobs and positions in the company outweigh the right of shareholders to meet for the purpose of considering their job performance.

On October 16, 2008, a group of Trinity Biotech ADR holders sent a request to Trinity Biotech calling for the convening of a special meeting of Trinity Biotech shareholders to consider the removal of the current Trinity Biotech directors and their replacement by a slate nominated by the ADR holders who requested the meeting. Thomas Reidy, a member of the group, announced today that company management had advised him by letter dated November 5, 2008 that they would not call the special meeting as requested.

In their refusal letter, the Trinity Biotech directors stated that their denial was based on a determination that the ADR holders, as contrasted with the ordinary shares they represent, do not have the authority under Irish law to call the meeting.

Commenting on Trinity Biotech's refusal to call the special meeting, Mr. Reidy stated that he was "disappointed but certainly not surprised" by the position taken by current management. Mr. Reidy pointed out that the group's original letter requesting the special meeting contains a demand that the Trinity Biotech directors take alternative steps to effectuate the special meeting if management is of the opinion that the requesting ADR holders did no
'/>"/>

SOURCE Thomas J. Reidy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
2. Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008
3. Trinity Biotech plc to Announce Second Quarter 2008 Financial Results on July 22, 2008
4. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
5. InterMune to Present at Deutsche Bank Biotech Boston Confab
6. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
7. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
8. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
9. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
10. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
11. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  NuGene International, ... aesthetic products for skin and hair rejuvenation, has ... as agency of record for investor relations and ... improve our distribution, sales and diversification strategies – ... current and prospective shareholders," stated Ali Kharazmi CEO ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Innovation ... are emerging from unexpected parts of the world ... From agriculture to manufacturing to health care, ... and environmental realities and socio-political trends shake the ... the key ingredient for CEOs to survive the ...
(Date:2/26/2015)... 26, 2015 Ceres, Inc . today ... Oracle PartnerNetwork. In attaining Gold Level membership, Ceres has ... Oracle-related knowledge in delivering Ceres, Persephone genome visualization software ... Originally developed for in-house use by Ceres, ... and out of massive amounts of genetic data, from ...
(Date:2/26/2015)... SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2015 ... for the treatment of cancer, today announced that ... present a corporate overview at the upcoming Cowen and ... Boston . Dr. McCarthy,s presentation will ... 2. About CytomX Therapeutics CytomX Therapeutics ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 2Ceres Becomes Oracle PartnerNetwork Gold Level Partner 3Ceres Becomes Oracle PartnerNetwork Gold Level Partner 4
... EMERYVILLE, Calif., Feb. 7 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... quarter 2008 financial results, for the quarter ended December,31, ... conference call to,discuss the earnings and to give a ... E. Freiman, President and Chief Executive,Officer, and Craig W. ...
... -- Total segment operating profit increased 77% when compared to the same ... 14% volume growth in the quarter, -- Fertilizer continued to benefit ... (In millions, except per share data and percentages), ... Quarter Ended ...
... ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ), ... Company,s marketing-enabling bioequivalence clinical study of ANX-530,(vinorelbine ... the 2008,American Association for Cancer Research (AACR) ... 16, 2008 in San Diego, CA., ...
Cached Biology Technology:Bunge Reports Fourth Quarter Net Income of $245 Million 2Bunge Reports Fourth Quarter Net Income of $245 Million 3Bunge Reports Fourth Quarter Net Income of $245 Million 4Bunge Reports Fourth Quarter Net Income of $245 Million 5Bunge Reports Fourth Quarter Net Income of $245 Million 6Bunge Reports Fourth Quarter Net Income of $245 Million 7Bunge Reports Fourth Quarter Net Income of $245 Million 8Bunge Reports Fourth Quarter Net Income of $245 Million 9Bunge Reports Fourth Quarter Net Income of $245 Million 10Bunge Reports Fourth Quarter Net Income of $245 Million 11Bunge Reports Fourth Quarter Net Income of $245 Million 12Bunge Reports Fourth Quarter Net Income of $245 Million 13Bunge Reports Fourth Quarter Net Income of $245 Million 14Bunge Reports Fourth Quarter Net Income of $245 Million 15Bunge Reports Fourth Quarter Net Income of $245 Million 16Bunge Reports Fourth Quarter Net Income of $245 Million 17Bunge Reports Fourth Quarter Net Income of $245 Million 18Bunge Reports Fourth Quarter Net Income of $245 Million 19Bunge Reports Fourth Quarter Net Income of $245 Million 20ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 2ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting 3
(Date:2/12/2015)... Feb. 12, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62/113114 for DISTRIBUTED METHOD AND SYSTEM ... The patent further establishes NXT-ID,s position in the emerging ... portfolio the ability for multiple devices to collaborate with ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , ... cancer, today announced that Murali Prahalad , Ph.D., president ... Medicine World Conference (PMWC) 2015: Silicon Valley, which is ... Mountain View, Calif. on January 26-28, 2015. ... Come of Age as Biomarkers." Last year, Epic Sciences was ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... (December 1, 2010) University of Minnesota School of ... international group of researchers that has identified 30 new ... in women. Many of these genes are also known ... to the multi-institutional study, only four genes had been ...
... If you think life,s too short, then you,re not alone. A team ... to live a very long life and they made important discoveries that ... featured on the cover of The FASEB Journal ( http://www.fasebj.org ... elegans , and in the process discovered a new metabolic state correlating ...
... new class of sensors able to detect multiple ... may soon be within reach thanks to the ... by Georgia Institute of Technology engineers. ... because of their applications in clinical screening, drug ...
Cached Biology News:U of M researcher helps unlock 30 new genes responsible for early onset puberty 2Longevity breakthrough: The metabolic state of mitochondria controls life span 2$4.3 million DARPA grant enables development of biological and chemical threat detector 2$4.3 million DARPA grant enables development of biological and chemical threat detector 3
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... exhibits very high activity in primer extension ... the quality of the enzyme, each lot ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/L; 1 tube of 1, 000 units enzyme/tube w/Buffer II and MgCl2...
... Enzyme concentration - 5 units/µL ,• High ... yields ,• Leaves an 'A' overhang ,• ... which exhibits very high activity in primer ... ensure the quality of the enzyme, each ...
Recombinant DNA polymerase from Thermus aquaticus expressed in E. coli; 5 units/uL; 25 tubes of 1, 000 units enzyme/tube w/ Buffer I...
Biology Products: